On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy

We aimed to analyze the serum level of a novel fibrosis marker, Mac-2-binding protein glycosylation isomer (M2BPGi), and its predictive value for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) under nucleot(s)ide analogue (NA) therapy. Serum M2BPGi levels were quantified in...

Descripción completa

Detalles Bibliográficos
Autores principales: Murata, Ayato, Amano, Nozomi, Sato, Sho, Tsuzura, Hironori, Tomishima, Ko, Sato, Shunsuke, Matsumoto, Kohei, Shimada, Yuji, Iijima, Katsuyori, Genda, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139452/
https://www.ncbi.nlm.nih.gov/pubmed/32192084
http://dx.doi.org/10.3390/ijms21062051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139452/
https://www.ncbi.nlm.nih.gov/pubmed/32192084
http://dx.doi.org/10.3390/ijms21062051

Ejemplares similares